Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the role of zoledronic acid in the treatment of premenopausal early breast cancer patients
- Discuss recent data on taxanes in both node-negative and node-positive breast cancer patients
- Relate the evidence for combining antiangiogenic and HER2-targeted therapies for the clinical management of patients with breast cancer
- Summarize data from recent studies on the continued use of trastuzumab after disease progression on a trastuzumab-containing regimen
- Recall the findings on prognosis in patients with BRCA mutations vs sporadic breast cancer patients
Topics covered include:
- ABCSG-12 Trial: Zoledronic Acid Improves Survival in Premenopausal Early Breast Cancer Patients
- GEICAM 9805 Trial: Docetaxel vs 5-FU in Adjuvant Regimen in Node-Negative Patients
- TAXit216: Adjuvant Docetaxel and Epirubicin in Node-Positive Early Breast Cancer
- New Agents to Target HER2-Positive Disease
- Phase II Trial of Lapatinib With or Without Pazopanib in HER2-Positive Patients
- Lapatinib Plus Bevacizumab in HER2-Positive Disease: First Data From Phase II Trial
- Capecitabine/Docetaxel Compared With Epirubicin/Docetaxel in First-Line Therapy
- Safety and Tolerability of Lapatinib and Trastuzumab Combined With Chemotherapy
- Eribulin Mesylate Neuropathy Data in Patients Previously Treated With an Anthracycline and a Taxane
- Prognosis in Hereditary Breast Cancer